Literature DB >> 15776277

Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.

Heydy V Bravo-Villalta1, Koujirou Yamamoto, Katsunori Nakamura, Ana Bayá, Yuko Okada, Ryuya Horiuchi.   

Abstract

OBJECTIVE: Several reports of CYP2C genetic polymorphism demonstrate its potential clinical role in determining both inter-individual and inter-ethnic differences in drug efficacy. We estimated the distribution of CYP2C9 and CYP2C19 common variants in the Bolivian population (a South American population), and compared these data with those from Asian, African, Caucasian and Oceanian populations.
METHODS: Genomic DNA was obtained from 778 unrelated healthy volunteers from Bolivia. The genotypic status of CYP2C9 and CYP2C19 was determined by means of polymerase chain reaction-restriction fragment length polymorphism.
RESULTS: Allelic and genotypic frequencies of CYP2C9 and CYP2C19 were determined for the Bolivian population, and comparison of the data with other ethnic groups revealed a lower CYP2C9*2 frequency (4.8%) than in Caucasians, but a higher frequency than in Asians; frequencies of CYP2C9*3 (3.0%) and CYP2C9 (0.4%) poor metabolizers (PMs) were similar to those seen in Asian populations. Frequencies of CYP2C19*2 (7.8%), CYP2C19*3 (0.1%), and CYP2C19 PMs (1.0%) in the Bolivian population were for the most part lower than in Caucasian, Asian, Oceanian and African populations.
CONCLUSION: This is the first study to investigate a South American population for genetic polymorphism in the CYP2C subfamily. The Bolivian population differs from most other ethnic groups in the incidence of CYP2C9 and CYP2C19 common variants that might be influenced by its admixture characteristics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776277     DOI: 10.1007/s00228-004-0890-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  47 in total

1.  Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4.

Authors:  M Garcia-Barceló; L Y Chow; H F Kum Chiu; Y K Wing; D T Shing Lee; K L Lam; M M Waye
Journal:  Clin Chem       Date:  1999-12       Impact factor: 8.327

2.  High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.

Authors:  A Kaneko; J K Lum; L Yaviong; N Takahashi; T Ishizaki; L Bertilsson; T Kobayakawa; A Björkman
Journal:  Pharmacogenetics       Date:  1999-10

3.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

4.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

5.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Authors:  M G Scordo; E Aklillu; U Yasar; M L Dahl; E Spina; M Ingelman-Sundberg
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 6.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

9.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.

Authors:  J A Goldstein; T Ishizaki; K Chiba; S M de Morais; D Bell; P M Krahn; D A Evans
Journal:  Pharmacogenetics       Date:  1997-02

Review 10.  Biochemistry and molecular biology of the human CYP2C subfamily.

Authors:  J A Goldstein; S M de Morais
Journal:  Pharmacogenetics       Date:  1994-12
View more
  24 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.

Authors:  Yipeng Ding; Dongchuan Xu; Xiyang Zhang; Hua Yang; Tingting Geng; Ping He; Jinjian Yao; Shengyang Yi; Heping Xu; Duoyi Wu; Xiang Wang; Tianbo Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

4.  Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype.

Authors:  Alma Faviola Favela-Mendoza; Gabriela Martinez-Cortes; Marcelo Hernandez-Zaragoza; Joel Salazar-Flores; Jose Francisco Muñoz-Valle; Victor Manuel Martinez-Sevilla; Noemi Yolanda Velazquez-Suarez; Hector Rangel-Villalobos
Journal:  J Genet       Date:  2015-03       Impact factor: 1.166

5.  Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Authors:  N S Bazan; N A Sabry; A Rizk; S Mokhtar; O A Badary
Journal:  Ir J Med Sci       Date:  2013-06-27       Impact factor: 1.568

6.  Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.

Authors:  Jorge Vicente; Fabricio González-Andrade; Antonia Soriano; Ana Fanlo; Begoña Martínez-Jarreta; Blanca Sinués
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

Review 7.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 8.  The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.

Authors:  M Constanza Camargo; Apolinaria García; Arnoldo Riquelme; William Otero; Claudia A Camargo; Tomas Hernandez-García; Roberto Candia; Michael G Bruce; Charles S Rabkin
Journal:  Am J Gastroenterol       Date:  2014-03-04       Impact factor: 10.864

9.  Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-28       Impact factor: 2.441

10.  Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.

Authors:  Joel Salazar-Flores; Luis A Torres-Reyes; Gabriela Martínez-Cortés; Rodrigo Rubi-Castellanos; Martha Sosa-Macías; José F Muñoz-Valle; César González-González; Angélica Ramírez; Raquel Román; José L Méndez; Andrés Barrera; Alfredo Torres; Rafael Medina; Héctor Rangel-Villalobos
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.